The effect of daily administration of prasterone ( 0 , 3.25 mg , 6.5 mg or 13mg ) for 12 weeks on FSD in 215 postmenopausal women with or without MSD at baseline was evaluated in a prospective , randomized , double-blind , and placebo-controlled phase III clinical trial .